Obesity Management

The program will include branded obesity glucagon-like peptide-1 medications, which will have a transparent monthly cost.

Providers can prescribe the 12.5 mg and 15 mg vials of tirzepatide starting July 7, with shipments beginning in early August.

Investigators find that patients with moderate weight loss or those who were weight resistant still had improvement in cardiometabolic health.

Investigators found that simvastatin added to escitalopram for patients with obesity and major depressive disorder did not have increased antidepressive effects.

Results from a phase 2 trial showed that semaglutide combined with trevogrumab, with or without garetosmab, helped patients preserve lean mass and achieve greater fat loss.

The data show a decrease in all-cause mortality for sustained midlife weight loss achieved without surgical or pharmacological interventions.

The new program aims to reduce costs for patients, with savings estimated at as much as $3600 per year.

Glucagon-like peptide-1 receptor agonists have been associated with improvements in quality of life (QOL), restrained eating, and emotional eating behavior.

Investigators report that patients experience weight loss with a reduced weekly dosage of the glucagon-like peptide-1 (GLP-1).

Semaglutide resulted in a significant reduction in the risk of MACE within the first 3 months of treatment compared to placebo.

Tirzepatide (Zepbound) demonstrated superiority compared to semaglutide (Wegovy) across the primary end point and 5 key secondary end points.

Patients often have anxiety about potential adverse effects, and experiencing adverse effects can affect patient adherence.

The nation’s largest PBM is placing Novo Nordisk’s premier weight-loss drug atop its formulary beginning July 1, 2025.

Although the market is expected to continue to become more popular, compounding pharmacies will no longer be allowed to manufacture these medications, as shortages have been listed as resolved.

Glucagon-like peptide-1 medications are the fastest-growing class of medication and will continue to be prevalent as more indications, such as sleep apnea, are added.

The authors emphasize the importance of multifaceted and team-based approaches to the management of diabetes.

Luke Turnock, PhD, MSc, discussed current trends in the promotion of lifestyle enhancement drugs for populations they are not approved for.

One asymptomatic patient did experience drug-induced liver injury that was resolved after discontinuation of danuglipron.

Investigators find 5 distinct obesity trajectories that influenced brain morphology, function, and cognition.

As of April 2, 2025, liraglutide remained in shortage, with the drug first entering the FDA database on July 18, 2023.

The outpatient endoscopic procedure modifies duodenal dysfunction and restores metabolic health.

Lydia Newsom, PharmD, discusses injection techniques, managing side effects, and the importance of collaboration between the healthcare team.

Lydia Newsom, PharmD, discuses how pharmacists can support patients using GLP-1s.

Researchers explored how social media advertising of lifestyle drugs contributes to the normalization of use for semaglutide, testosterone, and sildenafil.

On both an individual and societal level, researchers explored how social, cultural, and ethnic determinants impact the treatment and management of obesity.

Tirzepatide and semaglutide show long-term health care cost savings but, the high cost of the medications offset the savings.

Among various weights and diabetes diagnoses, researchers explored the differences in patients’ food perceptions when considering weight management and appetite.

Researchers compared changes in diet quality and waist-to-hip ratio during midlife with that of hippocampal connectivity and cognitive function in later life.

Approximately 89.7% of patients taking CagriSema achieve the coprimary end point of weight loss of 5% or more compared with 30.3% on the placebo.

Among postmenopausal women, researchers explored associations between intentional weight loss and waist circumference (WC) reduction and mortality.